Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good points..
Re: Javitt is top 1% of researchers. The guy isn’t going to go into this political playground half cocked. Once we get DMC approval and the papers peer reviewed, it will be go time. Not a moment sooner. The thing with research physicians and scientists of that caliber. They don’t succumb to hype and excitement. They don’t act impulsive. The go into the scientific community with their best evidence backed by the approval of other scientists before making a move. If this was to get out and become politicized, his reputation would be jeopardized. Patience is key here.
$RLFTF Really good presentation .. Great 20 min. on Aviptadil and the 21 Patients.
Aviptadil (RLF-100) For COVID-19: 21 Patients With Severe Refractory COVID Showing Improvements!
..saw that I think RLF-100 was pushed way in front many firsts and the things that are going on in the background says they're ramping up.. that and this crew has inside White House connections were employed by and worked with the FDA many times along w/foreign company issues partnering ..etc.. I don't know maybe they're trying to remain stealth to avoid being a victim of the bickering?
I actually don't have a problem with it.. I was just providing a solution.
..think we're going to get some BIG NEWS soon though...
..I've been away last 12 hours.. can't say I've seen any attacking.. I'm just looking forward to the truth about RLF-100 coming through in the next few days.. weeks and this turning into a runaway train.. gonna happen!!
I think you're right and we will be used alone and with others.. and I also see Andy's point.. give some an inch and they'll take a mile.. maybe JohnCM will be OK with these topics on his board and that will settle the issue?
https://investorshub.advfn.com/Coronavirus-COVID-19-Medical-Science-Plays-37857/
Mark Levin and Dr. Harvey Risch just took Dr. Fauci and The FDA out behind the back of the woodshed for a Whoopin!!! on Life, Liberty and Levin related the blocking of useful drugs during the A.I.D's pandemic to the blocking while in COVID-19
The next revolution w/Steve Hilton will talk Covid-19 w/Trump next..
Maybe that Phase 3 question was set up as a lead in to the next moves
Dr Qanta just mentioned lung injury as a side effect of plasma treatment.. guess RLF-100 will be cleaning up this mess also..
35 out of 100.. ugh !! that's what they are bragging about.. Phase 3 right to try.. Q .. here we go
Fox breaking in looks like it will be earlier than 6pm ? 2 min warning..
$RLFTF Really good presentation .. Great 20 min. on Aviptadil and the 21 Patients.
Aviptadil (RLF-100) For COVID-19: 21 Patients With Severe Refractory COVID Showing Improvements!
$RLFTF Really good presentation .. Great 20 min. on Aviptadil and the 21 Patients.
Aviptadil (RLF-100) For COVID-19: 21 Patients With Severe Refractory COVID Showing Improvements!
He'll need to defend his position so I'm guessing he'll mention a few therapeutics.
$RLFTF Uncle Gee Gee (CopyDD)
Summary of known facts about RLFTF: Aviptadil RLF-100 VIP
• Aviptadil is a repurposed erectile dysfunction drug, proven to be safe since 1970’s.
• Aviptadil blocks Covid from attaching to host cells in the lungs, prevents the cytokine storm, and reduces inflammation. This is a targeted trifecta for treating Covid.
• An inhaler version of Aviptadil will undergo clinical trials, with the intent to ultimately be used for in-home treatment of Covid cases. This study is expected to complete around Nov 31, with results being published sometime afterwards.
• Aviptadil is inexpensive and easy to manufacture.
• Aviptadil shows promise for other lung applications beyond Covid, which also needs to be studied and tested.
Stock/Company
• Relief Therapeutics holds the patent on Aviptadil. It is a small company in Switzerland, traded over the counter (OTC).
• NeuroRX is a private US-based partner with leadership that is well-connected at the highest levels of government and big pharma. They are guiding Relief Therapeutics through the FDA approval process.
• Company has $3M cash, but will need approx. another $20M to complete all 3 trials, including inhaler version.
• Unconfirmed: Most of the outstanding shares are owned by insiders.
• Chairman Raghuram (Ram) Selvaraju says there is no real need to raise capital via additional shares at this point, due to liquidity option provided by GEM.
• Speculation: Company may have recently raised enough additional capital to complete trials through Princeton Angels.
Manufacturing and Distribution
• Robert Bestoff, Chief of Operations, spent his career at Lilly & Pfizer. At Pfizer, he was head of entire neuro science and pain division and was responsible for $10b of drugs.
• Manufacturing program put together by Rich Siegel, former head of Johnson & Johnson’s drug portfolio.
• 2 Partnership arrangements are expected to be announced soon.
• “We are about to announce a partnership with the largest supplier of inhaled sterile drugs in the United States.” NeuroRX CEO Dr. Javitt
• “We are about to announce a partnership with a very large well-known public company that can get any drug to any hospital overnight” NeuroRX CEO Dr. Javitt
• “By October, we should be manufacturing enough drug for 100,000 people each month.” NeuroRX CEO Dr. Javitt
Clinical Trials
• Clinical Trial NCT04311697 – The initial clinical trial underway to test intravenously administered drug. Approximately 86 out of 122 patients have been recruited as of Aug 12, and the company’s data committee will begin reviewing the cases once they reach 102 patients. From there, they will present findings to the FDA. Speculation: Review could begin this week of 8/24; however, official publication of results could take several more weeks, but likely before October, due to Javitt’s comments about being able to ramp up production by October.
• Clinical Trial NCT04453839 – The FDA-approved Expanded Access program for treating patients who are too sick for clinical trials.
• Expanded Access results were released in a “pre-print” document, showing 19 of 21 patients have survived. These are the sickest of the sick (ICU, ventilators, ECMO patients). The pre-print is under peer review & expected to be officially released in the coming weeks.
• Clinical Trial NCT04360096 – A study of 288 patients to test an inhaler-version of RLF-100, intended to ultimately be used for in-home treatments. Estimated completion of trial is November 30th. According to Dr. Javitt: “We expect that half the people we enroll in our inhaled study are going to be people who are outpatients.”
Very good.. reposting...
$RLFTF Uncle Gee Gee (CopyDD)
Summary of known facts about RLFTF: Aviptadil RLF-100 VIP
• Aviptadil is a repurposed erectile dysfunction drug, proven to be safe since 1970’s.
• Aviptadil blocks Covid from attaching to host cells in the lungs, prevents the cytokine storm, and reduces inflammation. This is a targeted trifecta for treating Covid.
• An inhaler version of Aviptadil will undergo clinical trials, with the intent to ultimately be used for in-home treatment of Covid cases. This study is expected to complete around Nov 31, with results being published sometime afterwards.
• Aviptadil is inexpensive and easy to manufacture.
• Aviptadil shows promise for other lung applications beyond Covid, which also needs to be studied and tested.
Stock/Company
• Relief Therapeutics holds the patent on Aviptadil. It is a small company in Switzerland, traded over the counter (OTC).
• NeuroRX is a private US-based partner with leadership that is well-connected at the highest levels of government and big pharma. They are guiding Relief Therapeutics through the FDA approval process.
• Company has $3M cash, but will need approx. another $20M to complete all 3 trials, including inhaler version.
• Unconfirmed: Most of the outstanding shares are owned by insiders.
• Chairman Raghuram (Ram) Selvaraju says there is no real need to raise capital via additional shares at this point, due to liquidity option provided by GEM.
• Speculation: Company may have recently raised enough additional capital to complete trials through Princeton Angels.
Manufacturing and Distribution
• Robert Bestoff, Chief of Operations, spent his career at Lilly & Pfizer. At Pfizer, he was head of entire neuro science and pain division and was responsible for $10b of drugs.
• Manufacturing program put together by Rich Siegel, former head of Johnson & Johnson’s drug portfolio.
• 2 Partnership arrangements are expected to be announced soon.
• “We are about to announce a partnership with the largest supplier of inhaled sterile drugs in the United States.” NeuroRX CEO Dr. Javitt
• “We are about to announce a partnership with a very large well-known public company that can get any drug to any hospital overnight” NeuroRX CEO Dr. Javitt
• “By October, we should be manufacturing enough drug for 100,000 people each month.” NeuroRX CEO Dr. Javitt
Clinical Trials
• Clinical Trial NCT04311697 – The initial clinical trial underway to test intravenously administered drug. Approximately 86 out of 122 patients have been recruited as of Aug 12, and the company’s data committee will begin reviewing the cases once they reach 102 patients. From there, they will present findings to the FDA. Speculation: Review could begin this week of 8/24; however, official publication of results could take several more weeks, but likely before October, due to Javitt’s comments about being able to ramp up production by October.
• Clinical Trial NCT04453839 – The FDA-approved Expanded Access program for treating patients who are too sick for clinical trials.
• Expanded Access results were released in a “pre-print” document, showing 19 of 21 patients have survived. These are the sickest of the sick (ICU, ventilators, ECMO patients). The pre-print is under peer review & expected to be officially released in the coming weeks.
• Clinical Trial NCT04360096 – A study of 288 patients to test an inhaler-version of RLF-100, intended to ultimately be used for in-home treatments. Estimated completion of trial is November 30th. According to Dr. Javitt: “We expect that half the people we enroll in our inhaled study are going to be people who are outpatients.”
$RLFTF From a Dr. Yo 8/22, Impressive paper.
https://t.co/Q4arpKOmZl?amp=1
- morokoy
Wow so many possible uses for Aviptadil! Good write up.
mmh Good Q, but they may just go ahead with a mix.. we're still in..
3 to 21 days results showed ..that should give hope to the families using this treatment.. great results in the worst cases.. these results can no longer be denied.. hope everything goes well in the next trials.. but after 50 years of use .. negative things would be known by now.. No ?
$RLFTF Really good presentation .. Great 20 min. on Aviptadil and the 21 Patients.
Aviptadil (RLF-100) For COVID-19: 21 Patients With Severe Refractory COVID Showing Improvements!
$RLFTF Really good presentation .. Great 20 min. on Aviptadil and the 21 Patients.
Aviptadil (RLF-100) For COVID-19: 21 Patients With Severe Refractory COVID Showing Improvements!
Write up (copy) /not mine/ Interesting op-ed post
So even though there was a leak, Relief had to disclose that they did not leak the information as per Compliance. Notice that they did not denied the content only that unauthorized people disclose the information.
Then they directed us to SSRN which has the OFFICIAL release (Basically the same as the leak information).....
Notice the following points from the OFFICIAL release directly from SSRN. Awesome and Encouraging news.
1) 19 of 21 patients have survived (90% survival rate) (Without RLF-100 probably all these people would have not make it)
2) Improve radiographic appearance (X-Rays) was seen in both lungs on 17 patients of the 21 and improvement in one lung of the remaining 2 patients. (Basically improvement on ALL 19 patients' lungs)
3) Complete remission from respiratory failure in 9 Patients. Ongoing Improvement in 10 patients (Again improvement on all 19 Patients)
4) 7 Patients Discharged from the Hospital. 7 taken out from ICU and 5 remain in the ICU (14 patients out of the 19 OUT OF ICU- Basically 74% of the 19 Patients taken out from ICU)
5) ECMO (worst condition possible)-Out of 5 Patients, 3 have been decannulated and 2 have been DISCHARGED. (100% IMPROVEMENT on all 5 Patients that were on ECMO)
Final Comment: The short term outcomes in these 21 patients represent a DRAMATIC RESPONSE in patients who are excluded from all other trials of COVID therapeutics. Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect.
Remember these 21 Patients were basically just waiting to die due to this terrible disease. RLF-100 was the hope they and their families were waiting for. 19 out of those 21 Patients now have a second chance thanks to RLF-100.
Maybe FDA will step in and say we have seen enough, FDA Approval granted (Dr. Javitt explained that this can happen during his interview last week).
Relief mentioned in their press release "The manuscript has been submitted for peer review to a leading scientific journal. We await the results of the ongoing placebo-controlled trial in order to assess the magnitude of clinical effect."
Basically they are saying "I have taken the exam, I know that I passed based on my answers (results). I am just waiting for the professor to grade it" (Peer review). And by the way aside from the results of these 21 patients,, I am pending the results of the ongoing placebo controlled trial which basically will have the same outcomes......."
$RLFTF Reminder. 6pm est tonight. Coronavirus (COVID-19)
Aviptadil (RLF-100) For COVID-19: 21 Patients With Severe Refractory COVID Showing Improvements!
WhiteBoard style discussion on a pre-print case series (partially authored by the company that owns Aviptadil) on 21 patients with severe refractory COVID-19 all on ventilators and several on ECMO who failed multiple other therapies including remdesevir, tocilizumab, convalescent plasma, etc.
They were granted FDA emergency use authorization for intravenous Aviptadil (RLF-100). They saw significant improvements in the PaO2:FiO2 ratio, improvements in lung imaging, decreases in inflammatory markers, and improvements in the WHO ordinal scale. At 21 days, there was only a single death secondary to COVID-19 in this severely ill population.
Many had been discharged home on room air! Of note, this is a case series in pre-print partially authored by the company that owns Aviptadil, so there are many potential limitations!
$RLFTF Sounds like the FDA are liking the results and don't want to leave current lives at risk out..
"The FDA also granted an expanded access protocol for RLF-100 (aviptadil), from Geneva-based Relief Therapeutics Holdings AG and Radnor, Pa.-based Neurorx Inc., to those patients who are ineligible for enrollment in clinical trials" -
From the Article in Bio-World
$RLFTF Sounds like the FDA are liking the results and don't want to leave current lives at risk out..
"The FDA also granted an expanded access protocol for RLF-100 (aviptadil), from Geneva-based Relief Therapeutics Holdings AG and Radnor, Pa.-based Neurorx Inc., to those patients who are ineligible for enrollment in clinical trials" -
From the Article in Bio-World
8 in ago: 8/22 AM Update: X-rays not taken yet today. Vent is 70% and ECMO 100%. O2 is 96% on the monitor. Blood pressure is stable this morning. The new medication was slowed down last night to see if that would help in the fluctuation in oxygenation they were seeing. The nurse was not sure if the doctor would recommend starting the 5th dose or not. If they decide to start it, then that would probably begin around 2:30 this afternoon. #searcystrong
https://www.facebook.com/groups/344854903191256/
WHO warns coronavirus vaccine alone won't end pandemic: 'We cannot go back to the way things were' https://cnb.cx/2CNYU7X
WHO warns coronavirus vaccine alone won't end pandemic: 'We cannot go back to the way things were' https://cnb.cx/2CNYU7X
COVID-19 (Industry related) Remdesivir, the only FDA-authorized drug for COVID-19, may not significantly improve outcomes, a study found
https://www.businessinsider.com/remdesivir-may-not-significantly-improve-covid-19-outcomes-study-2020-8
COVID-19 (Industry related) Remdesivir, the only FDA-authorized drug for COVID-19, may not significantly improve outcomes, a study found
https://www.businessinsider.com/remdesivir-may-not-significantly-improve-covid-19-outcomes-study-2020-8
30 min. ago - The vent is up because they rolled him over from lying on his stomach to now lying him on his back. More good news is coming as he’s receiving tons of prayers and RLF-100.
$RLFTF The Results
Trial 3 includes a series of 21 consecutive patients with Acute Respiratory Failure in Critical COVID-19 and multiple co-morbidities, treated with intravenous VIP.
So far, 19 out of 21 of them have survived. At the moment, August 20, 7 patients were discharged from the hospital, 7 sent to intermediate care, and 5 remain in the ICU. As often in those cases, blood oxygenation is very low and can be lethal.
As you can see below, the use of RLF-100™, dramatically improved blood oxygenation.
A promising anti-COVID drug you have probably never heard of
https://medium.com/@alexschroeti/a-promising-anti-covid-drug-you-have-probably-never-heard-of-d6cae8072da6
$RLFTF The Results
Trial 3 includes a series of 21 consecutive patients with Acute Respiratory Failure in Critical COVID-19 and multiple co-morbidities, treated with intravenous VIP.
So far, 19 out of 21 of them have survived. At the moment, August 20, 7 patients were discharged from the hospital, 7 sent to intermediate care, and 5 remain in the ICU. As often in those cases, blood oxygenation is very low and can be lethal.
As you can see below, the use of RLF-100™, dramatically improved blood oxygenation.
A promising anti-COVID drug you have probably never heard of
https://medium.com/@alexschroeti/a-promising-anti-covid-drug-you-have-probably-never-heard-of-d6cae8072da6
..way too early for talk about a R/S but we can talk possible Government emergency grants and other Countries throwing money at this Company FOR FREE to battle covid-19 and the company doing a share buyback with overwhelming profits taken in a year from now.. we're LOOKING GOOD along with the latest patient data :)
..early info released on the trials look good and give hope to the Searcy journey.., they may have to fight a little more because of possible smoke inhalation in the past while in the job..?
..another possible use for RLF-100 ..actually during that Dr Drew webcast they brought up several possible uses..
6 treated for smoke inhalation after Beaver Falls apartment building fire https://www.wpxi.com/news/top-stories/6-hurt-apartment-building-fire-beaver-falls/TGK465323FFJFN6PDUFB3JUBIA/
SWX: RLF
0.54 CHF -0.016 (2.86%)
Aug 21, 12:17 PM
link
Update: 8/20 (around 12PM)
X-rays seem to be about the same as earlier this morning. The vent is currently set at 90% and ECMO at 96%. Blood pressure and O2 levels remain steady.
..maybe they raised the % for overnight..?
https://www.facebook.com/groups/344854903191256/